Turnstone Biologics Corp.
TSBX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | -73.7% | -27.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | 85.5% | 97% | 98% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | $0 |
| % Margin | – | -301.1% | -43.1% | 32.6% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | $0 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | – | -285.9% | -42.1% | 32.8% |
| EPS | -3.07 | -2.73 | -1.39 | 1.5 |
| % Growth | -12.5% | -96.4% | -192.7% | – |
| EPS Diluted | -3.07 | -2.73 | -1.39 | 1.5 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | – | -291.3% | -38.9% | 35.3% |